{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"67.65","upperLimit":"84.80","value":"70.41"},{"groupId":"OG001","lowerLimit":"24.15","upperLimit":"84.40","value":"54.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"154"}],"units":"Participants"}],"title":"Participants with >= 5% PD-L1 Expression,"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.05","upperLimit":"61.04","value":"38.677"},{"groupId":"OG001","lowerLimit":"11.14","upperLimit":"26.51","value":"16.56"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"300"},{"groupId":"OG001","value":"299"}],"units":"Participants"}],"title":"Participants with < 5% PD-L1 Expression,"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Participants with Non-quantifiable PD-L1 Expression"}],"denoms":[{"counts":[{"groupId":"OG000","value":"453"},{"groupId":"OG001","value":"453"}],"units":"Participants"}],"description":"Recurrence-free survival by PD-L1 Expression(5% tumor cell membrane expression)","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg IV q2 wks and Ipilimumab placebo IV q3 wks for 4 doses then q12 wks starting at Wk 24","id":"OG000","title":"Nivolumab 3 mg/kg"},{"description":"Ipilimumab 10 mg/kg IV q3 wks for 4 doses then q12 wks starting at Wk 24 and Nivolumab placebo IV q2 wks","id":"OG001","title":"Ipilimumab 10 mg/kg"}],"paramType":"MEDIAN","populationDescription":"All randomized Participants","reportingStatus":"POSTED","timeFrame":"up to 106.6 months","title":"Recurrence-free Survival by PD-L1 Expression","type":"SECONDARY","unitOfMeasure":"Months"}